Aspen Ends Potential Deal For European Business
Aspen has terminated discussions with a potential partner around a deal to help it to optimize its European pharmaceuticals business.
You may also be interested in...
Disposing of its Nutritionals business allows Aspen to fully focus on pharmaceuticals, while the firm is looking to drive organic growth with an emphasis on its Emerging Markets division, optimizing its complex manufacturing capabilities and seeking collaborations in territories where it “lacks sufficient critical mass”. These are among the measures Aspen has identified as it outlines four priorities for the firm, as the group shifts from being a regional generics company to a global specialty business.
South Africa’s Aspen will invest an additional ZAR3.4 billion (US$238 million) at its domestic Port Elizabeth manufacturing site, in “South Africa’s single biggest pharmaceutical investment”.